Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 7:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metformin Clear all
Completed Phase 4 Interventional Results available

Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

NCT00729326
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, sitagliptin, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Sep 13, 2026, 7:44 PM EDT
Completed Phase 3 Interventional

Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione

NCT00044447
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Glimepiride
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2008 · Synced Sep 13, 2026, 7:44 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

NCT07033585
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes, China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes
Drug
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
Industry
Eligibility
24 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 13, 2026, 7:44 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Precision Dosing of Metformin in Youth With T2D

NCT06120881
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
10 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 13, 2026, 7:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Metformin Effect on Brain Function in Insulin Resistant Elderly People

NCT03733132
View directory record Official record
Conditions
Insulin Resistance, Obesity, Obesity, Abdominal
Interventions
Metformin Hydrochloride, Placebo Oral Tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 13, 2026, 7:44 PM EDT
Completed Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

NCT06221969
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cagrilintide, Semaglutide, Tirzepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
117
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 13, 2026, 7:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity

NCT06638671
View directory record Official record
Conditions
Exercise Capacity, Metformin
Interventions
Metformin Hydrochloride, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 13, 2026, 7:44 PM EDT
Recruiting Phase 2 Interventional

The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

NCT05414409
View directory record Official record
Conditions
Type 1 Diabetes, Obesity
Interventions
Metformin
Drug
Lead sponsor
Heba M. Ismail
Other
Eligibility
11 Years to 18 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 13, 2026, 7:44 PM EDT
Recruiting Phase 3 Interventional

MetfOrmin BenefIts Lower Extremities With Intermittent Claudication

NCT05132439
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Metformin ER, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered

NCT01068743
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
saxagliptin, metformin, saxagliptin + metformin (FDC tablet)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 13, 2026, 7:44 PM EDT
Completed Phase 2 Interventional Results available

Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth

NCT00617240
View directory record Official record
Conditions
Weight Gain
Interventions
metformin, placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
10 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Sep 13, 2026, 7:44 PM EDT
Terminated Phase 1 Interventional

Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes

NCT00332085
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Chromium Picolinate
Drug
Lead sponsor
Bastyr University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Kenmore, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2007 · Synced Sep 13, 2026, 7:44 PM EDT
Completed Phase 3 Interventional Results available

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

NCT00765817
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
placebo, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
40
States / cities
Peoria, Arizona • Phoenix, Arizona • Buena Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Sep 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional

Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer

NCT02339168
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide, Metformin Hydrochloride
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 13, 2026, 7:44 PM EDT
Terminated Early Phase 1 Interventional

Brain Imaging in the Diabetes Prevention Program Outcomes Study

NCT03757910
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-MK-6240, 11C-PIB
Drug
Lead sponsor
José A. Luchsinger
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants

NCT02884089
View directory record Official record
Conditions
Healthy
Interventions
Abemaciclib, Metformin, Iohexol, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Sep 13, 2026, 7:44 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus

NCT00885378
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin plus metformin IR, Placebo plus metformin IR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 78 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Concord, California • Fountain Valley, California • Lomita, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Sep 13, 2026, 7:44 PM EDT
Completed Phase 2 Interventional Results available

Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease

NCT02656017
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Metformin, Placebo
Drug · Other
Lead sponsor
Kyongtae Ty Bae, M.D., Ph.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 13, 2026, 7:44 PM EDT
Completed Phase 2 Interventional Results available

Metformin in Amnestic Mild Cognitive Impairment

NCT00620191
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Metformin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Sep 13, 2026, 7:44 PM EDT
Terminated Phase 3 Interventional Results available

Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes

NCT01834274
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Fasiglifam (TAK-875), Fasiglifam (TAK-875) Placebo, Sitagliptin, Sitagliptin Placebo, Metformin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
44
States / cities
Huntsville, Alabama • Chandler, Arizona • Glendale, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Sep 13, 2026, 7:44 PM EDT
Completed Phase 4 Interventional Results available

The Health Influences of Puberty (HIP) Study

NCT01775813
View directory record Official record
Conditions
Obesity, Insulin Resistance, Gonadal Dysfunction, Type 2 Diabetes
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 13, 2026, 7:44 PM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00518882
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
61
States / cities
Birmingham, Alabama • Goodyear, Arizona • Artesia, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 13, 2026, 7:44 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

NCT02229396
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Exantide with Dapagliflozin, Exentide, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
76
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Sep 13, 2026, 7:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects

NCT05526690
View directory record Official record
Conditions
Hypertension
Interventions
Metformin, CIN-107
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 13, 2026, 7:44 PM EDT